Stoke Therapeutics (STOK) EBITDA (2018 - 2026)

Stoke Therapeutics has reported EBITDA for 9 years, with the latest figure at -$50.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 144.86% year-over-year to -$50.7 million; the trailing twelve-month figure through Mar 2026 stood at -$169.8 million (down 438.42% YoY), and the FY2025 full-year result was -$6.2 million, up 93.05% from the prior year.
• EBITDA for Q1 2026 stood at -$50.7 million, up from -$57.8 million in the prior quarter.
• The five-year high for EBITDA was $112.9 million in Q1 2025, with the low at -$57.8 million in Q4 2025.
• Average EBITDA over 5 years is -$20.7 million, with a median of -$25.7 million recorded in 2024.
• Peak annual rise in EBITDA reached 528.56% in 2025, while the deepest fall reached 435.58% in 2025.
• Tracing STOK's EBITDA over 5 years: stood at -$25.1 million in 2022, then fell by 6.8% to -$26.8 million in 2023, then jumped by 59.76% to -$10.8 million in 2024, then sank by 435.58% to -$57.8 million in 2025, then advanced by 12.41% to -$50.7 million in 2026.
• The last three EBITDA figures came in at -$50.7 million (Q1 2026), -$57.8 million (Q4 2025), and -$38.0 million (Q3 2025), per Business Quant data.

Peer Comparison